BioLife Solutions, Inc. revised earnings guidance for the full year 2023. For the period, the company expects revenue at the low end of the previously announced guidance range of $144 million to $158 million, which assumes flat to modest sequential growth for its cell processing platform in the fourth quarter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.01 USD | +0.39% | -0.83% | +10.83% |
05-09 | Earnings Flash (BLFS) BIOLIFE SOLUTIONS Posts Q1 Revenue $31.7M, vs. Street Est of $24.9M | MT |
04-18 | BioLife Solutions Completes Divestment of Global Cooling Subsidiary | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.83% | 813M | |
-4.91% | 183B | |
+0.46% | 108B | |
-3.62% | 67.51B | |
+3.26% | 50.67B | |
+9.11% | 44.7B | |
+3.66% | 40.95B | |
+6.39% | 26.8B | |
+3.83% | 26.71B | |
+15.04% | 24.62B |
- Stock Market
- Equities
- BLFS Stock
- News BioLife Solutions, Inc.
- BioLife Solutions, Inc. Revises Earnings Guidance for the Full Year 2023